BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 31412289)

  • 1. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
    Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
    Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
    Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
    Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of phytochemicals against Keap1- NRF2 interaction to reactivate NRF2 Functioning: Pharmacoinformatics based approach.
    Akmal A; Javaid A; Hussain R; Kanwal A; Zubair M; Ashfaq UA
    Pak J Pharm Sci; 2019 Nov; 32(6(Supplementary)):2823-2828. PubMed ID: 32024620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.
    Kim S; Indu Viswanath AN; Park JH; Lee HE; Park AY; Choi JW; Kim HJ; Londhe AM; Jang BK; Lee J; Hwang H; Lim SM; Pae AN; Park KD
    Neuropharmacology; 2020 May; 167():107989. PubMed ID: 32032607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
    Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
    Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
    Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
    Pallesen JS; Tran KT; Bach A
    J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
    Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
    J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
    Lu MC; Shao HL; Liu T; You QD; Jiang ZY
    Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
    Bello M; Morales-González JA
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish.
    Raghunath A; Nagarajan R; Sundarraj K; Palanisamy K; Perumal E
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):259-270. PubMed ID: 30861618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pterostilbene-mediated Nrf2 activation: Mechanistic insights on Keap1:Nrf2 interface.
    Bhakkiyalakshmi E; Dineshkumar K; Karthik S; Sireesh D; Hopper W; Paulmurugan R; Ramkumar KM
    Bioorg Med Chem; 2016 Aug; 24(16):3378-86. PubMed ID: 27312421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity.
    Lu MC; Zhang X; Wu F; Tan SJ; Zhao J; You QD; Jiang ZY
    J Med Chem; 2019 Jul; 62(14):6796-6813. PubMed ID: 31283229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil elastase inhibitor suppresses oxidative stress in obese asthmatic rats by activating Keap1/Nrf2 signaling pathway.
    Zheng JQ; Zhang GR; Li J; Bi HW
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):361-369. PubMed ID: 30657578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoflavone biochanin A, a novel nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element activator, protects against oxidative damage in HepG2 cells.
    Liang F; Cao W; Huang Y; Fang Y; Cheng Y; Pan S; Xu X
    Biofactors; 2019 Jul; 45(4):563-574. PubMed ID: 31131946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review.
    Singh E; Matada GSP; Abbas N; Dhiwar PS; Ghara A; Das A
    Inflammopharmacology; 2021 Oct; 29(5):1347-1355. PubMed ID: 34373972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico Evidence for Binding of Pentacyclic Triterpenoids to Keap1-Nrf2 Protein-Protein Binding Site.
    Kamble SM; Patel HM; Goyal SN; Noolvi MN; Mahajan UB; Ojha S; Patil CR
    Comb Chem High Throughput Screen; 2017; 20(3):215-234. PubMed ID: 28024463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
    Heightman TD; Callahan JF; Chiarparin E; Coyle JE; Griffiths-Jones C; Lakdawala AS; McMenamin R; Mortenson PN; Norton D; Peakman TM; Rich SJ; Richardson C; Rumsey WL; Sanchez Y; Saxty G; Willems HMG; Wolfe L; Woolford AJ; Wu Z; Yan H; Kerns JK; Davies TG
    J Med Chem; 2019 May; 62(9):4683-4702. PubMed ID: 30973731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of polypodiside as a Keap1-dependent Nrf2 activator attenuating oxidative stress and accumulation of extracellular matrix in glomerular mesangial cells under high glucose.
    Yao H; Zhang N; Zhang W; Li J; Hua H; Li Y
    Bioorg Med Chem; 2020 Dec; 28(24):115833. PubMed ID: 33166928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.